Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesPhase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
Clinical Cancer Research, 06/03/09
Satoh T et al. - YM155 was safely administered to patients with advanced refractory solid tumors by 168-hour continuous i.v. infusion in 21-day cycles. The MTD was determined to be 8.0 mg/m2/d. The safety profile, plasma concentrations achieved, and antitumor activity observed merit further studies with this survivin suppressant, alone and in combination regimens.
Related Articles
Characterization of human organic cation transporter 1 (OCT1/SLC22A1)-, and OCT2 (SLC22A2)-mediated transport of YM155 monobromide, a novel survivin suppressant
Drug Metabolism and Disposition, 11/23/09
Relevance Score: 64%
Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09
Relevance Score: 46%
Survivin Expression as a Strong Indicator of Recurrence in Urothelial Bladder Cancer. Predictive Value of Nuclear versus Cytoplasmic Staining
Anticancer Research, 11/11/09
Relevance Score: 45%
Significance of P-glycoprotein, P53, and survivin expression in renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations, 12/15/09
Relevance Score: 43%
Caspase 2-mediated tumor suppression involves survivin gene silencing
Oncogene, 11/30/09
Relevance Score: 42%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/18/09
How do providers assess antihypertensive medication adherence in medical encounters?
Journal of General Internal Medicine, 12/18/09
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Should routine screening by mammography be replaced by a more selective service of risk assessment/risk management?
Women's Health, 12/18/09
Pain in patients with lung cancer: Pathophysiology and treatment
Lung Cancer, 12/18/09
Initial testing of topotecan by the pediatric preclinical testing program
Pediatric Blood & Cancer, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor